期刊
EXPERT REVIEW OF VACCINES
卷 9, 期 3, 页码 299-307出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERV.09.163
关键词
chimeric vaccines; intranasal delivery; mucosal antibody; mucosal immunity; multivalent vaccines; norovirus; oral delivery; vaccine platforms; virus-like particle; VLP
类别
资金
- NIH [U19-AI062150]
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI062150] Funding Source: NIH RePORTER
Noroviruses (NoV) cause the great majority of epidemic nonbacterial gastroenteritis in humans. Expression of the capsid protein in recombinant systems, including insect and plant cells, yields assembly of virus-like particles (VLPs) that mimic the antigenic structure of authentic virions, and are relatively acid- and heat-stable. Norwalk virus (NV), the prototype NOV, has been studied extensively, and Norwalk virus-like particles (NVLPs) produced in insect cells and plants are immunogenic in mice and humans when delivered orally, stimulating the production of systemic and mucosal anti-NV antibodies. NVLPs are also highly immunogenic when delivered intranasally, provoking antibodies at levels similar to orally delivered VLP at much lower doses. Oral and nasal delivery of NVLPs efficiently produces antibodies at distal mucosal sites, which suggests that NVLPs could be used to deliver heterologous peptide antigens by production of genetic fusion chimeric capsid proteins. Examination of norovirus VLP surface structures and receptor binding motifs facilitates identification of potential sites for insertion of foreign peptides that will minimally affect the efficiency of VLP assembly and receptor binding. Thus, there is strong potential to use norovirus VLPs as vaccine-delivery vehicles.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据